Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China
Chronic hepatitis C (CHC) is a chronic and progressive disease prevalent in the whole world and greatly threatens human health. The launch of direct-acting antiviral agents (DAAs) brings a revolutionary change in the treatment of CHC. In recent years, several DAAs have been marketed in foreign count...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Hepatology
2018-02-01
|
| Series: | Linchuang Gandanbing Zazhi |
| Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=8745 |
| Summary: | Chronic hepatitis C (CHC) is a chronic and progressive disease prevalent in the whole world and greatly threatens human health. The launch of direct-acting antiviral agents (DAAs) brings a revolutionary change in the treatment of CHC. In recent years, several DAAs have been marketed in foreign countries and have achieved good clinical effects, and in China, some DAAs have also been approved and widely used in clinical practice, which contributes to the increase in the cure rate of hepatitis C. This article analyzes the features, clinical effects, and indications of DAAs marketed in China and reviews published real-world studies, in order to help clinicians select proper treatment regimens based on patients′ features. |
|---|---|
| ISSN: | 1001-5256 1001-5256 |